Current Issue : July - September Volume : 2019 Issue Number : 3 Articles : 6 Articles
Introduction. Tendon adhesion to surrounding tissues is the most common complication reported after tendon repair. To date,\neffective solutions to prevent tendon injury are still lacking. Materials and Methods. A total of 89 patients with flexor tendon injury\nin zone II were recruited.The patients were divided into a control group, a poly-DL-lactic acid (PDLLA) group, and an amnion\ngroup according to the different tendon treatments applied. The control group was not subjected to other treatments. PDLLA\nand bioamniotic membranes were, respectively, used to wrap broken ends in the PDLLA and amnion membrane groups. The\npatients were followed at 1, 2, 3, 6, and 12 months after surgery and the ranges of active flexion and extension lag in the proximal\nand distal interphalangeal joints were evaluated. Results.The means of total active ranges of motion of the interphalangeal joints\n(excluding rupture cases) in the PDLLA and amnion groups did not significantly differ between each other but significantly differed\nfrom that of the control group. Statistical analysis showed a significant difference in the clinical grades of the outcomes among the\ncontrol, PDLLA, and amnion groups.Theincidence of complications in the control and PDLLAgroups was found to be significantly\nhigher than that in the amniotic membrane group; no significant difference was observed between the control and PDLLA groups.\nConclusion. In this study, freeze-dried amniotic membrane transplantation was applied to promote healing of the flexor tendon in\nzone II and prevent adhesion. This technique presents a newmethod to solve the issue of tendon adhesion after repair. Clinical Trial\nRegistration.The trial was registered by identifier ChiCTR1900021769....
Clinical trials in attention-deficit/hyperactivity disorder (ADHD) have typically measured\noutcome using clinician ratings on the Attention-Deficit/Hyperactivity Disorder Rating Scale, Fourth\nEdition (ADHD-RS-IV) and the Clinical Global Impression-Improvement (CGI-I) scale. Remission has\nbeen defined as an endpoint score of less than or equal to 18 on the ADHD-RS-IV (or a mean score\nof 1). Responders have been defined as patients who achieve a CGI-I score of much or very much\nimproved (1 or 2). There is a lack of agreement in the literature on what percent change in symptoms\non the ADHD-RS-IV should be used to define improvement or remission. This study uses data\nfrom a clinical trial of a methylphenidate extended release (MPH-MLR; Aptensio XR®) phase III\nclinical trial to attempt to determine the percent change of symptoms that best corresponds with\nimprovement and remission�����.....
Objective. This study was performed to determine the efficacy and tolerability/safety of IQP-AE-103 on body weight reduction in\noverweight to moderately obese adults. Methods. A double-blind, randomized, placebo-controlled trial involved one hundred and\neight subjects (BMI between 25 and 35 kg/m^2) that were randomly assigned to either the low-dose or the high-dose IQP-AE-103\ngroup, or the placebo group. Following a 2-week run-in period, subjects received two capsules of investigational product after\nthree daily main meals for 12 weeks. Subjects were instructed to maintain a nutritionally balanced hypocaloric diet according to\nthe individualâ??s energy requirement. Body weight, body fat, and waist and hip circumference were measured at baseline, and after\n2, 4, 8, and 12 weeks. Subjects also rated their feelings of hunger and fullness using visual analogue scales, and food craving on a 5-\npoint scale at the same time intervals. Blood samplings for safety laboratory parameters were taken before and at the end of the\nstudy. Results. After 12 weeks of intake, the high-dose IQP-AE-103 group had a significantly greater weight loss compared with the\nplaceboâ?¦â?¦â?¦â?¦â?¦â?¦.....
Shengxuening (SXN) tablet is extracted from the excrement of the silkworm and has effects on hematopoiesis. The main\ncomponents of SXN are chlorophyll derivatives and sodium iron chlorophyllin (SIC). The present study aims to investigate the\nefficiency and safety of SXN on iron deficiency anemia. This phase IV, multicenter, open-label, randomized clinical trial was\nconducted in 31 hospitals in China from June 2001 to April 2002. Adults and children were randomly divided into low-dose (LSXN),\nmedium-dose (M-SXN), and high-dose (H-SXN) groups, respectively. The course of treatment was 1 month. Peripheral\nhemogram levels and iron status were examined before and after treatment. Adults in all three dose groups demonstrated a\nsignificant increase in hemoglobin (HGB) concentration. Children who received SXN treatment in medium and high doses also\ndemonstrated increasedHGB concentration. Reticulocyte counts increased at the end of treatment in theM-SXNandH-SXN adult\ngroups and in theM-SXNchild group. For both children and adults, SXN in the three dose groups was found to significantly elevate\nred blood cell level,mean corpuscular volume, mean corpuscular hemoglobin, and mean corpuscular hemoglobin concentration.\nThe total effective rate in the SXN-treated group reached 84.8%. Theincidence of adverse events was 4.07%.Themost common side\neffects were nausea (2.83%), diarrhea (0.74%), and rash (0.25%). SXN was proved to be efficient and safe for adults and children\nwith iron deficiency anemia....
Background. Chimeric antigen receptor T (CAR-T) cell therapy has achieved unprecedented success among hematologic tumors,\nbut its role in treating solid tumors is still unclear. Methods. A comprehensive search of electronic databases up to June 1, 2018, was\ncarried out by two independent reviewers. We included studies which focused on the association between CAR-T cell therapy and\npatient response rate and survival time in solid tumors. Results. 22 studies with 262 patients were included in our meta-analysis. The\noverall pooled response rate of CAR-T cell therapy was 9% (95% confidence interval (CI): 4-16%). Subgroup analysis (analyses)\ndemonstrated that CAR-T therapy could perform its best therapeutic effect on neuroblastoma, while barely works among\ngastrointestinal malignancies. Moreover, the treatment efficacy was not significantly impacted by different treatment strategies\n(lymphodepletion before T cell infusion, transfection method, cell culture duration, persistence of CAR-T cells, transfection\nefficacy, total cell dose, and administration of IL-2). Only T cell culture duration was associated with better clinical prognosis.\nConclusions. Although CAR-T cell therapy did not have satisfactory responses in solid tumors, researchers were still holding an\noptimistic attitude towards its future efficacy with more modifications of its structure....
Introduction. Opioid assisted treatment (OAT) with buprenorphine (BUP) is front-line medical maintenance intervention for\nillicit and prescription opioid use disorder (OUD). In many clinics, opioid medication is dispensed for several days for selfadministration.\nThis provides flexibility to the patient but may compromise the effectiveness of OAT because of nonadherence\nor medication diversion. OAT can be delivered as an entirely supervised intervention, but many patients discontinue treatment\nunder this arrangement and dispensing costs may be prohibitive. An alternative is to enable patients to receive take-home doses\ncontingent on OAT adherence guided by a medication management framework using Therapeutic Drug Monitoring (TDM)\nalongside negative urine drug screens (UDS) to provide evidence of abstinence. TDM is recommended to monitor adherence\nwith BUP but it has not been applied in OAT programs and evaluation research to date. Methods. The Suboxone Treatment and\nRecovery Trial (STAR-T) is a single site, 16-week, parallel-group, randomised controlled trial. The aim of the study is to determine\nthe effectiveness of a medication management framework including TDM and UDS to enable patients enrolled on outpatient\nOAT (with buprenorphine/naloxone [sublingual film formulation; BUP/NX-F; Suboxone(TM)]) to receive stepped take-home doses.\nFollowing stabilisation during inpatient care, adult participants with illicit or prescription OUD were allocated (1:1) to receive (1)\nBUP/NX-F plus medication management for take-home doses based on TDM, UDS, and contingency management protocol (the\nexperimental group) or (2) BUP/NX-F plus UDS only (treatment-as-usual, the control group).The primary outcome is the mean\npercentage of negativeUDS over 16 weeks. Thesecondary outcome is treatment retention defined as completion of 16 weeks ofOAT\nwithout interruption.There will be an exploratory analysis of the association between participant characteristics, clinical data, and\noutcomes. Conclusions. Providing BUP/NX-F take-home doses contingent on adherence and opioid abstinence may enable OAT\nto be delivered flexibly and effectively. Trial Registration. ISRCTN41645723 is retrospectively registered on 15/11/2015....
Loading....